Who Paid My Doc
Andrew Ragula
General Practice Biloxi, MS Medical Doctor
NPI 1578615001 CMS profile 379454
967 Cedar Lake Rd, Biloxi, MS 39532
General payments
$852
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Andrew Ragula of Biloxi, MS is reported in the CMS Open Payments database as having received $852 across 45 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 77th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $196 | 11 | |
| 2022 | General | $115 | 7 | |
| 2021 | General | $457 | 22 | |
| 2020 | General | $60 | 3 | |
| 2019 | General | $24 | 2 |
Beside peers
- Andrew Ragula
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Andrew Ragula were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Andrew Ragula | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $24 | $107 | $37–$285 | $163 |
| 2020 | $60 | $75 | $25–$213 | $114 |
| 2021 | $457 | $93 | $30–$272 | $132 |
| 2022 | $115 | $103 | $36–$279 | $149 |
| 2023 | $196 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $0 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 28 drugsPart D claims
635
Drug cost
$32,466
Branded share of claims
13.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | Brand | 20 | $11,661 | |
| Januvia Sitagliptin Phosphate | Brand | 12 | $8,817 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 12 | $5,883 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 29 | $757 | |
| Gabapentin | Generic | 27 | $718 | |
| Omeprazole | Generic | 21 | $452 | |
| Atorvastatin Calcium | Generic | 57 | $437 | |
| Pantoprazole Sodium | Generic | 33 | $319 | |
| Amlodipine Besylate | Generic | 61 | $283 | |
| Methocarbamol | Generic | 11 | $268 |
The 10 drugs with the highest cost, of 28 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Records
45 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other General Practice in Mississippi
Delphine Shannon
General Practice · Gulfport, MS
William McClendon
General Practice · Pascagoula, MS
Michael Anthony
General Practice · Starkville, MS
Steven Demetropoulos
General Practice · Ocean Springs, MS
Richmond McCarty
General Practice · Saltillo, MS
Emily Grenn
General Practice · Jackson, MS
Related records
General Practice in Mississippi
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Mississippi
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.